Research projects in the last 10 years:
2026-2029 European Union under Horizon Europe. EP PerMed JTC2025. EPPERMED2025-088–pRCC-TREAT. Proyecto: «Molecular-based stratification of metastatic papillary renal cell carcinoma to personalize treatment strategies» Coordinator: Rodríguez-Antona, IIBM
2025-2028 Spanish Ministry of Science and Innovation PID2024-158237OB-I00. Project: “Uncovering therapeutic opportunities for metastatic renal cell carcinomas: genomic definition and molecular mechanisms. THERo-RenCa”
2018-2026 Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla (FISEVI). Project: “Caracterización molecular de subpoblaciones de tumores de células germinales avanzados resistentes a cisplatino: diseño de una firma genética”
2022-2025 Spanish Ministry of Science and Innovation PID2021-128312OB-I00. Project: “Molecular alterations of metastatic renal cell carcinoma of clinical significance for antitumor drug response. kidneyALT”
2022-2023 Fundación HNA Premio investigación científica/Fundación para la Investigación Biomédica del Hospital 12 de Octubre. Project: “Pharmacogenomic study of the toxicity of trastuzumab-deruxtecan in breast cancer patients”.
2020-2022 Pfizer. Project: “Non-clear cell renal cell carcinoma genomics for the discovery of Axitinib predictive markers
2020-2021 Asociación Española Contra el Cáncer (AECC) Ideas Semilla 2020. Project: “Bypassing Nonsense Mediated mRNA Decay to enhance immunotherapy response in cancer”
2019-2021 Spanish Ministry of Economy and Competitiveness RTI2018-095039-B-I00. Project: “Improving the clinical management of advanced renal cell carcinoma through genomic technologies (RCC-MARKER)”
2019-2020 Grupo Español de Tumores Neuroendocrinos y Endocrinos (GETNE). Biomarkers study in:. Project: “Estudio Fase II para evaluar la actividad y seguridad de TH302 en combinación con sunitinib para pacientes con tumores neuroendocrinos pancreáticos (pNET) bien o moderadamente diferenciados metastásicos no tratados previamente”.
2018-2019 Pfizer. Project: “Whole Exome Sequencing in extreme sunitinib responder patients to identify predictive markers: integration of germline and tumor variation”.
2017-2018 Spanish Oncology GenitoUrinary Group (SOGUG). Project: “Estudio observacional prospectivo y multicéntrico, para identificar biomarcadores con valor pronóstico y predictivo de respuesta a fármacos antiangiogénicos aprobados en el tratamiento en primera línea del carcinoma de células renales metastásico/localmente “
2016-2018 Spanish Ministry of Economy and Competitiveness SAF2015-64850-R. Project: “Identification of genetic markers and physiopathologic factors predictive of the peripheral neuropathy of paclitaxel and of other oncologic drugs: massive sequencing of candidate genes”
2016-2018 Spanish Oncology GenitoUrinary Group (SOGUG). Project: “Estudio multicéntrico retrospectivo para explorar la eficacia de diferentes secuencias de tratamiento e identificar biomarcadores de respuesta a axitinib”
2015-2016 Spanish Ministry of Economy and Competitiveness SAF2015-70820-ERC. Project: “Predicting antiangiogenic drug response in cancer: markers and mechanisms”
2014-2016 Pfizer. Project: “microRNAs as predictors of response to sunitinib in patients with clear cell renal cell carcinoma”
2012-2015 Leiden University Medical Center. Project: “Cross-validation of the genetic polymorphisms associated with sunitinib
